Literature DB >> 24753149

Do difficulties in swallowing medication impede the use of hydroxyurea in children?

ElShadey Bekele1, Courtney D Thornburg, Amanda M Brandow, Mukta Sharma, Arlene M Smaldone, Zhezhen Jin, Nancy S Green.   

Abstract

BACKGROUND: Use of hydroxyurea (HU) in children with sickle cell disease (SCD) may be hampered by its formulation as a capsule and the limited availability of liquid HU. PROCEDURE: At four Pediatric SCD clinics, parents of children with SCD ages 5-17 years were surveyed about their children's medication use and ability to swallow medication. Data were stratified by HU therapy and analyzed using descriptive statistics, Chi square tests, Fisher exact tests and univariate analysis.
RESULTS: Of the 116 parents surveyed, 97% were the primary caregiver. One fourth (26%) of parents reported that their child's difficulty swallowing medication interfered with daily medication use. Age-related differences were found in ability to swallow medication, but not by HU use. Children taking HU were more likely to take multiple daily medications, with more frequent dosing schedules. Among 65 HU users, children using the liquid formulation (28%, n = 18) were younger than capsule users (P < 0.0001). Nonetheless, half of liquid HU users were aged 8-13. Children using liquid HU were more likely to have difficulties swallowing medication than those who use HU capsules (OR 4.29, 95% CI 1.14-16.18, P = 0.032). Few had received training for swallowing medication.
CONCLUSIONS: One fourth of surveyed parents viewed swallowing as challenging to daily medication use. These findings suggest that difficulty swallowing capsules is a fairly frequent barrier to for children prescribed HU, especially for younger children. HU use appears more likely in families with daily and more complex medication schedules. Coaching for swallowing capsules may improve HU utilization and adherence.
© 2014 Wiley Periodicals, Inc.

Entities:  

Keywords:  adherence; capsules; hydroxyurea; medication; swallowing

Mesh:

Substances:

Year:  2014        PMID: 24753149      PMCID: PMC4184198          DOI: 10.1002/pbc.25073

Source DB:  PubMed          Journal:  Pediatr Blood Cancer        ISSN: 1545-5009            Impact factor:   3.167


  19 in total

1.  National Institutes of Health Consensus Development Conference statement: hydroxyurea treatment for sickle cell disease.

Authors:  Otis W Brawley; Llewellyn J Cornelius; Linda R Edwards; Vanessa Northington Gamble; Bettye L Green; Charles Inturrisi; Andra H James; Danielle Laraque; Magda Mendez; Carolyn J Montoya; Brad H Pollock; Lawrence Robinson; Aaron P Scholnik; Melissa Schori
Journal:  Ann Intern Med       Date:  2008-05-05       Impact factor: 25.391

Review 2.  A systematic review of barriers and interventions to improve appropriate use of therapies for sickle cell disease.

Authors:  Carlton Haywood; Mary Catherine Beach; Sophie Lanzkron; John J Strouse; Renee Wilson; Haeseong Park; Catherine Witkop; Eric B Bass; Jodi B Segal
Journal:  J Natl Med Assoc       Date:  2009-10       Impact factor: 1.798

3.  Adherence to hydroxyurea therapy in children with sickle cell anemia.

Authors:  Courtney D Thornburg; Agustin Calatroni; Marilyn Telen; Alex R Kemper
Journal:  J Pediatr       Date:  2009-11-01       Impact factor: 4.406

4.  Experience with a pill-swallowing enhancement aid.

Authors:  Shelley Diamond; Danielle C Lavallee
Journal:  Clin Pediatr (Phila)       Date:  2010-01-28       Impact factor: 1.168

5.  Prevalence of daily medication adherence among children with sickle cell disease: a 1-year retrospective cohort analysis.

Authors:  Niti G Patel; Terianne Lindsey; Robert C Strunk; Michael R DeBaun
Journal:  Pediatr Blood Cancer       Date:  2010-09       Impact factor: 3.167

6.  Hydroxyurea in children with sickle cell disease: practice patterns and barriers to utilization.

Authors:  Amanda M Brandow; Danielle L Jirovec; Julie A Panepinto
Journal:  Am J Hematol       Date:  2010-08       Impact factor: 10.047

7.  Hydroxyurea use in sickle cell disease: the battle with low prescription rates, poor patient compliance and fears of toxicities.

Authors:  Amanda M Brandow; Julie A Panepinto
Journal:  Expert Rev Hematol       Date:  2010-06       Impact factor: 2.929

Review 8.  Hydroxyurea for sickle cell disease: a systematic review for efficacy and toxicity in children.

Authors:  John J Strouse; Sophie Lanzkron; Mary Catherine Beach; Carlton Haywood; Haeseong Park; Catherine Witkop; Renee F Wilson; Eric B Bass; Jodi B Segal
Journal:  Pediatrics       Date:  2008-12       Impact factor: 7.124

Review 9.  Optimizing oral medications for children.

Authors:  Julie A Mennella; Gary K Beauchamp
Journal:  Clin Ther       Date:  2008-11       Impact factor: 3.393

Review 10.  Extemporaneous drug formulations.

Authors:  Milap C Nahata; Loyd V Allen
Journal:  Clin Ther       Date:  2008-11       Impact factor: 3.393

View more
  6 in total

1.  Greater number of perceived barriers to hydroxyurea associated with poorer health-related quality of life in youth with sickle cell disease.

Authors:  Arlene Smaldone; Deepa Manwani; Nancy S Green
Journal:  Pediatr Blood Cancer       Date:  2019-04-02       Impact factor: 3.167

2.  Hydroxyurea Initiation Among Children With Sickle Cell Anemia.

Authors:  Sarah L Reeves; Hannah K Jary; Jennifer P Gondhi; Jean L Raphael; Lynda D Lisabeth; Kevin J Dombkowski
Journal:  Clin Pediatr (Phila)       Date:  2019-05-21       Impact factor: 1.168

3.  Pharmacokinetics and bioequivalence of a liquid formulation of hydroxyurea in children with sickle cell anemia.

Authors:  Jeremie H Estepp; Chiara Melloni; Courtney D Thornburg; Paweł Wiczling; Zora Rogers; Jennifer A Rothman; Nancy S Green; Robert Liem; Amanda M Brandow; Shelley E Crary; Thomas H Howard; Maurine H Morris; Andrew Lewandowski; Uttam Garg; William J Jusko; Kathleen A Neville
Journal:  J Clin Pharmacol       Date:  2015-10-15       Impact factor: 3.126

4.  Stability evaluation of compounded hydroxyurea 100 mg/mL oral liquids using a novel analytical method involving chemical derivatization.

Authors:  Daphné Coache; Mihaela Friciu; Ruth Bernine Marcellin; Lola Bonnemain; Annie Viau; V Gaëlle Roullin; Jean-Marc Forest; Grégoire Leclair
Journal:  PLoS One       Date:  2022-06-24       Impact factor: 3.752

5.  Tablet/Capsule Size Variation Among the Most Commonly Prescribed Medications for Children in the USA: Retrospective Review and Firsthand Pharmacy Audit.

Authors:  Laura Jacobsen; Kathy Riley; Brian Lee; Kathleen Bradford; Ravi Jhaveri
Journal:  Paediatr Drugs       Date:  2016-02       Impact factor: 3.022

6.  Hydroxyurea: Pattern of Use, Patient Adherence, and Safety Profile in Patients with Sickle Cell Disease in Oman.

Authors:  Jimmy Jose; Refaat Abdullah Elsadek; Beena Jimmy; Prasad George
Journal:  Oman Med J       Date:  2019-07
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.